Naturally occurring anti-cancer agents targeting EZH2.

[1]  S. A. Ganai,et al.  Plant Derived Inhibitor Sulforaphane in Combinatorial Therapy Against Therapeutically Challenging Pancreatic Cancer. , 2017, Anti-cancer agents in medicinal chemistry.

[2]  A. Sahebkar,et al.  Curcumin as a natural regulator of monocyte chemoattractant protein-1. , 2017, Cytokine & growth factor reviews.

[3]  A. Sahebkar,et al.  Is There a Role for Curcumin Supplementation in the Treatment of Non-Alcoholic Fatty Liver Disease? The Data Suggest Yes. , 2017, Current pharmaceutical design.

[4]  A. Sahebkar,et al.  Curcumin: An Effective Inhibitor of Interleukin-6. , 2017, Current pharmaceutical design.

[5]  Kapil Kumar,et al.  Synthetic and Medicinal Prospective of Structurally Modified Curcumins. , 2016, Current topics in medicinal chemistry.

[6]  R. Eckert,et al.  The Ezh2 polycomb group protein drives an aggressive phenotype in melanoma cancer stem cells and is a target of diet derived sulforaphane , 2016, Molecular carcinogenesis.

[7]  J. Visvader,et al.  Dysregulation of histone methyltransferases in breast cancer – Opportunities for new targeted therapies? , 2016, Molecular oncology.

[8]  A. Sahebkar,et al.  Curcumin: A new candidate for melanoma therapy? , 2016, International journal of cancer.

[9]  Y. Panahi,et al.  Curcumin Lowers Serum Lipids and Uric Acid in Subjects With Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial , 2016, Journal of cardiovascular pharmacology.

[10]  S. Bo,et al.  Effect of curcumin on circulating interleukin-6 concentrations: A systematic review and meta-analysis of randomized controlled trials. , 2016, Pharmacological research.

[11]  S. Asgary,et al.  Treatment of Non‐alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo‐controlled Trial , 2016, Phytotherapy research : PTR.

[12]  A. Sahebkar,et al.  Difluorinated Curcumin: A Promising Curcumin Analogue with Improved Anti-Tumor Activity and Pharmacokinetic Profile. , 2016, Current pharmaceutical design.

[13]  M. Caraglia,et al.  High EZH2 expression is correlated to metastatic disease in pediatric soft tissue sarcomas , 2016, Cancer Cell International.

[14]  L. Rozek,et al.  Transcriptomic profiling of curcumin-treated human breast stem cells identifies a role for stearoyl-coa desaturase in breast cancer prevention , 2016, Breast Cancer Research and Treatment.

[15]  M. Nishimura,et al.  Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non‐small‐cell lung cancer cells , 2016, Cancer science.

[16]  Koraljka Gall Trošelj,et al.  Polycomb repressive complex’s evolutionary conserved function: the role of EZH2 status and cellular background , 2016, Clinical Epigenetics.

[17]  A. Sahebkar,et al.  Curcumin downregulates human tumor necrosis factor-α levels: A systematic review and meta-analysis ofrandomized controlled trials. , 2016, Pharmacological research.

[18]  K. Nakano,et al.  Polycomb-dependent epigenetic landscape in adult T-cell leukemia. , 2016, Blood.

[19]  Hua Jiang,et al.  Anti-cancer effects of curcumin on lung cancer through the inhibition of EZH2 and NOTCH1 , 2016, Oncotarget.

[20]  D. Dixon,et al.  An ornamental plant targets epigenetic signaling to block cancer stem cell-driven colon carcinogenesis. , 2016, Carcinogenesis.

[21]  G. Zhai,et al.  Oral bioavailability of curcumin: problems and advancements , 2016, Journal of drug targeting.

[22]  Wen-Wei Chang,et al.  Resveratrol suppresses myofibroblast activity of human buccal mucosal fibroblasts through the epigenetic inhibition of ZEB1 expression , 2016, Oncotarget.

[23]  A. Goel,et al.  Epigallocatechin-3-gallate targets cancer stem-like cells and enhances 5-fluorouracil chemosensitivity in colorectal cancer , 2016, Oncotarget.

[24]  Liang Shen,et al.  How does curcumin work with poor bioavailability? Clues from experimental and theoretical studies , 2016, Scientific Reports.

[25]  C. Roberts,et al.  Targeting EZH2 in cancer , 2016, Nature Medicine.

[26]  Y. Panahi,et al.  Antioxidant and anti-inflammatory effects of curcuminoid-piperine combination in subjects with metabolic syndrome: A randomized controlled trial and an updated meta-analysis. , 2015, Clinical nutrition.

[27]  G. Bowden,et al.  The effect of sulforaphane on histone deacetylase activity in keratinocytes: Differences between in vitro and in vivo analyses , 2015, Molecular carcinogenesis.

[28]  Y. Li,et al.  Role of Glycol Chitosan-incorporated Ursolic Acid Nanoparticles in the Treatment of Osteosarcoma , 2015 .

[29]  F. Zheng,et al.  Activation of SAPK/JNK mediated the inhibition and reciprocal interaction of DNA methyltransferase 1 and EZH2 by ursolic acid in human lung cancer cells , 2015, Journal of experimental & clinical cancer research : CR.

[30]  F. Zheng,et al.  Activation of SAPK/JNK mediated the inhibition and reciprocal interaction of DNA methyltransferase 1 and EZH2 by ursolic acid in human lung cancer cells , 2015, Journal of Experimental & Clinical Cancer Research.

[31]  M. Caraglia,et al.  EZH2 is increased in paediatric T-cell acute lymphoblastic leukemia and is a suitable molecular target in combination treatment approaches , 2015, Journal of experimental & clinical cancer research : CR.

[32]  Shu-Huei Wang,et al.  Curcumin-Mediated HDAC Inhibition Suppresses the DNA Damage Response and Contributes to Increased DNA Damage Sensitivity , 2015, PloS one.

[33]  M. Banach,et al.  Effect of curcuminoids on oxidative stress: A systematic review and meta-analysis of randomized controlled trials , 2015 .

[34]  V. Thakur,et al.  Epigenetic induction of tissue inhibitor of matrix metalloproteinase‐3 by green tea polyphenols in breast cancer cells , 2015, Molecular carcinogenesis.

[35]  R. Cabo,et al.  Resveratrol supplementation: Where are we now and where should we go? , 2015, Ageing Research Reviews.

[36]  A. Sahebkar,et al.  Analgesic Efficacy and Safety of Curcuminoids in Clinical Practice: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. , 2015, Pain medicine.

[37]  G. Ferns,et al.  An investigation of the effects of curcumin on anxiety and depression in obese individuals: A randomized controlled trial , 2015, Chinese Journal of Integrative Medicine.

[38]  D. Wodarz,et al.  Curcumin mediates chemosensitization to 5-fluorouracil through miRNA-induced suppression of epithelial-to-mesenchymal transition in chemoresistant colorectal cancer. , 2015, Carcinogenesis.

[39]  M. Ciccozzi,et al.  Analysis of the ORFK1 hypervariable regions reveal distinct HHV-8 clustering in Kaposi’s sarcoma and non-Kaposi’s cases , 2015, Journal of experimental & clinical cancer research : CR.

[40]  Y. Panahi,et al.  Investigation of the Efficacy of Adjunctive Therapy with Bioavailability‐Boosted Curcuminoids in Major Depressive Disorder , 2015, Phytotherapy research : PTR.

[41]  Qingsong Wang,et al.  Quantitative Nuclear Proteomics Identifies that miR-137-mediated EZH2 Reduction Regulates Resveratrol-induced Apoptosis of Neuroblastoma Cells* , 2014, Molecular & Cellular Proteomics.

[42]  A. Sahebkar,et al.  Curcuminoid Treatment for Knee Osteoarthritis: A Randomized Double‐Blind Placebo‐Controlled Trial , 2014, Phytotherapy research : PTR.

[43]  Xinchen Sun,et al.  Targets and molecular mechanisms of triptolide in cancer therapy. , 2014, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[44]  Y. Panahi,et al.  Lipid-modifying effects of adjunctive therapy with curcuminoids-piperine combination in patients with metabolic syndrome: results of a randomized controlled trial. , 2014, Complementary therapies in medicine.

[45]  Kristian Helin,et al.  Chromatin repressive complexes in stem cells, development, and cancer. , 2014, Cell stem cell.

[46]  Byung Jin Byun,et al.  Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors. , 2014, Bioorganic & medicinal chemistry letters.

[47]  Dong-Eun Kim,et al.  Ursolic acid and its natural derivative corosolic acid suppress the proliferation of APC-mutated colon cancer cells through promotion of β-catenin degradation. , 2014, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[48]  A. Sahebkar.  Are Curcuminoids Effective C‐Reactive Protein‐Lowering Agents in Clinical Practice? Evidence from a Meta‐Analysis , 2014, Phytotherapy research : PTR.

[49]  G. Ferns,et al.  Investigation of the Effects of Curcumin on Serum Cytokines in Obese Individuals: A Randomized Controlled Trial , 2014, TheScientificWorldJournal.

[50]  Fuqing Zeng,et al.  Methyl jasmonate sensitizes human bladder cancer cells to gambogic acid‐induced apoptosis through down‐regulation of EZH2 expression by miR‐101 , 2014, British journal of pharmacology.

[51]  A. Sahebkar.  Curcuminoids for the management of hypertriglyceridaemia , 2014, Nature Reviews Cardiology.

[52]  M. Shakibaei,et al.  Curcumin Chemosensitizes 5-Fluorouracil Resistant MMR-Deficient Human Colon Cancer Cells in High Density Cultures , 2014, PloS one.

[53]  S. Orkin,et al.  Polycomb repressive complex 2 regulates normal hematopoietic stem cell function in a developmental-stage-specific manner. , 2014, Cell stem cell.

[54]  A. Sahebkar,et al.  Curcuminoids Modulate Pro‐Oxidant–Antioxidant Balance but not the Immune Response to Heat Shock Protein 27 and Oxidized LDL in Obese Individuals , 2013, Phytotherapy research : PTR.

[55]  S. Orkin,et al.  Targeted Disruption of the EZH2/EED Complex Inhibits EZH2-dependent Cancer , 2013, Nature chemical biology.

[56]  D. Nam,et al.  Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. , 2013, Cancer cell.

[57]  A. Jankowska,et al.  Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies , 2013, Leukemia.

[58]  A. Bishayee,et al.  Ursolic acid in cancer prevention and treatment: molecular targets, pharmacokinetics and clinical studies. , 2013, Biochemical pharmacology.

[59]  Tim J. Wigle,et al.  Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2 , 2013, Proceedings of the National Academy of Sciences.

[60]  K. Hahn,et al.  An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1. , 2013, ACS chemical biology.

[61]  Madhusudhan R. Papasani,et al.  YY1 controls Igκ repertoire and B‐cell development, and localizes with condensin on the Igκ locus , 2013, The EMBO journal.

[62]  E. Flescher,et al.  Enhanced killing of cervical cancer cells by combinations of methyl jasmonate with cisplatin, X or alpha radiation , 2013, Investigational New Drugs.

[63]  A. Sahebkar.  Why it is necessary to translate curcumin into clinical practice for the prevention and treatment of metabolic syndrome? , 2013, BioFactors.

[64]  G. Ferns,et al.  Effects of Supplementation with Curcuminoids on Dyslipidemia in Obese Patients: A Randomized Crossover Trial , 2013, Phytotherapy research : PTR.

[65]  M. Geng,et al.  Curcumin Induces Cell Death and Restores Tamoxifen Sensitivity in the Antiestrogen-Resistant Breast Cancer Cell Lines MCF-7/LCC2 and MCF-7/LCC9 , 2013, Molecules.

[66]  M. Loda,et al.  EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent , 2012, Science.

[67]  B. Bao,et al.  Hypoxia-Induced Aggressiveness of Pancreatic Cancer Cells Is Due to Increased Expression of VEGF, IL-6 and miR-21, Which Can Be Attenuated by CDF Treatment , 2012, PloS one.

[68]  P. Atadja,et al.  Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation , 2012, Proceedings of the National Academy of Sciences.

[69]  D. Noh,et al.  EZH2 generates a methyl degron that is recognized by the DCAF1/DDB1/CUL4 E3 ubiquitin ligase complex. , 2012, Molecular cell.

[70]  Y. Panahi,et al.  A randomized controlled trial on the anti-inflammatory effects of curcumin in patients with chronic sulphur mustard-induced cutaneous complications , 2012, Annals of clinical biochemistry.

[71]  Tim J. Wigle,et al.  A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. , 2012, Nature chemical biology.

[72]  Yan Liu,et al.  EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations , 2012, Nature.

[73]  Y. Idaghdour,et al.  Synergistic antileukemic action of a combination of inhibitors of DNA methylation and histone methylation. , 2012, Leukemia research.

[74]  S. Shankar,et al.  Inhibition of sonic hedgehog pathway and pluripotency maintaining factors regulate human pancreatic cancer stem cell characteristics , 2012, International journal of cancer.

[75]  M. Hadjzadeh,et al.  Alcea rosea root extract as a preventive and curative agent in ethylene glycol-induced urolithiasis in rats , 2012, Indian journal of pharmacology.

[76]  M. Amiri,et al.  Improvement of sulphur mustard-induced chronic pruritus, quality of life and antioxidant status by curcumin: results of a randomised, double-blind, placebo-controlled trial , 2011, British Journal of Nutrition.

[77]  R. Eckert,et al.  Sulforaphane Suppresses Polycomb Group Protein Level via a Proteasome-Dependent Mechanism in Skin Cancer Cells , 2011, Molecular Pharmacology.

[78]  R. Eckert,et al.  (-)-Epigallocatechin-3-gallate and DZNep reduce polycomb protein level via a proteasome-dependent mechanism in skin cancer cells. , 2011, Carcinogenesis.

[79]  M. Mimeault,et al.  Potential applications of curcumin and its novel synthetic analogs and nanotechnology-based formulations in cancer prevention and therapy , 2011, Chinese medicine.

[80]  Ying Xiong,et al.  Antibacterial and anti-inflammatory effects of extracts and fractions from Polygonum capitatum. , 2011, Journal of ethnopharmacology.

[81]  A. Chase,et al.  Aberrations of EZH2 in Cancer , 2011, Clinical Cancer Research.

[82]  Jun Zhao,et al.  AN N-terminal Smac peptide sensitizes human prostate carcinoma cells to methyl jasmonate-induced apoptosis. , 2011, Cancer letters.

[83]  Yan Chen,et al.  Role of triptolide in cell proliferation, cell cycle arrest, apoptosis and histone methylation in multiple myeloma U266 cells. , 2010, European journal of pharmacology.

[84]  Sang-Woon Choi,et al.  Epigenetics: A New Bridge between Nutrition and Health. , 2010, Advances in nutrition.

[85]  A. Mills.  Throwing the cancer switch: reciprocal roles of polycomb and trithorax proteins , 2010, Nature Reviews Cancer.

[86]  R. Hu,et al.  Gambogic acid triggers DNA damage signaling that induces p53/p21(Waf1/CIP1) activation through the ATR-Chk1 pathway. , 2010, Cancer letters.

[87]  Y. Zeng,et al.  Curcumin induces down-regulation of EZH2 expression through the MAPK pathway in MDA-MB-435 human breast cancer cells. , 2010, European journal of pharmacology.

[88]  P. Atadja,et al.  Polycomb Target Genes Are Silenced in Multiple Myeloma , 2010, PloS one.

[89]  Kristian Helin,et al.  Characterization of an antagonistic switch between histone H3 lysine 27 methylation and acetylation in the transcriptional regulation of Polycomb group target genes , 2010, Nucleic acids research.

[90]  R. Eckert,et al.  The Bmi-1 polycomb protein antagonizes the (-)-epigallocatechin-3-gallate-dependent suppression of skin cancer cell survival. , 2010, Carcinogenesis.

[91]  L. Zhang,et al.  Inhibition of tumor growth and induction of apoptosis in prostate cancer cell lines by overexpression of tissue inhibitor of matrix metalloproteinase-3 , 2010, Cancer Gene Therapy.

[92]  Rameen Beroukhim,et al.  An oncogene–tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-κB , 2010, Nature Medicine.

[93]  Yan Chen,et al.  Triptolide alters histone H3K9 and H3K27 methylation state and induces G0/G1 arrest and caspase-dependent apoptosis in multiple myeloma in vitro. , 2010, Toxicology.

[94]  Ryan D. Morin,et al.  Somatic mutation of EZH2 (Y641) in Follicular and Diffuse Large B-cell Lymphomas of Germinal Center Origin , 2010, Nature Genetics.

[95]  Peter A. Jones,et al.  DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation , 2009, Molecular Cancer Therapeutics.

[96]  S. Dhanasekaran,et al.  Repression of E-cadherin by the polycomb group protein EZH2 in cancer , 2008, Oncogene.

[97]  J. Simon,et al.  Roles of the EZH2 histone methyltransferase in cancer epigenetics. , 2008, Mutation research.

[98]  M. Shimizu,et al.  Green Tea Extracts for the Prevention of Metachronous Colorectal Adenomas: A Pilot Study , 2008, Cancer Epidemiology Biomarkers & Prevention.

[99]  Gordon B Mills,et al.  Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers , 2008, Molecular carcinogenesis.

[100]  Wenjun Guo,et al.  The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.

[101]  Mingyao Liu,et al.  Gambogic acid inhibits angiogenesis and prostate tumor growth by suppressing vascular endothelial growth factor receptor 2 signaling. , 2008, Cancer research.

[102]  L. Bagella,et al.  Importance of Ezh2 polycomb protein in tumorigenesis process interfering with the pathway of growth suppressive key elements , 2008, Journal of cellular physiology.

[103]  Qiang Yu,et al.  Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. , 2007, Genes & development.

[104]  L. Wallrath,et al.  Connections between epigenetic gene silencing and human disease. , 2007, Mutation research.

[105]  Kelly M. McGarvey,et al.  The cancer epigenome--components and functional correlates. , 2006, Genes & development.

[106]  Anke Sparmann,et al.  Polycomb silencers control cell fate, development and cancer , 2006, Nature Reviews Cancer.

[107]  R. Kobayashi,et al.  CUL4–DDB1 ubiquitin ligase interacts with multiple WD40-repeat proteins and regulates histone methylation , 2006, Nature Cell Biology.

[108]  Hai-wei Zhang,et al.  Gambogic acid-induced G2/M phase cell-cycle arrest via disturbing CDK7-mediated phosphorylation of CDC2/p34 in human gastric carcinoma BGC-823 cells. , 2006, Carcinogenesis.

[109]  K. Yanagihara,et al.  Expression of the enhancer of zeste homolog 2 is correlated with poor prognosis in human gastric cancer , 2006, Cancer science.

[110]  D. Wazer,et al.  Suppression of Wnt Signaling by the Green Tea Compound (–)-Epigallocatechin 3-Gallate (EGCG) in Invasive Breast Cancer Cells , 2006, Journal of Biological Chemistry.

[111]  A. Singh,et al.  Multiple biological activities of curcumin: a short review. , 2006, Life sciences.

[112]  Johan Eide,et al.  Expression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancer. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[113]  S. Baylin,et al.  Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction? , 2006, Nature Reviews Cancer.

[114]  O. Halvorsen,et al.  EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[115]  Zhong Zuo,et al.  Danshen: An Overview of Its Chemistry, Pharmacology, Pharmacokinetics, and Clinical Use , 2005, Journal of clinical pharmacology.

[116]  Chang-Zheng Chen,et al.  MicroRNAs as oncogenes and tumor suppressors. , 2005, The New England journal of medicine.

[117]  J. Köllermann,et al.  Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas. , 2005, International journal of molecular medicine.

[118]  Y. Arsenijévic,et al.  Ink4a and Arf differentially affect cell proliferation and neural stem cell self-renewal in Bmi1-deficient mice. , 2005, Genes & development.

[119]  Q. You,et al.  Gambogic acid inhibits proliferation of human lung carcinoma SPC-A1 cells in vivo and in vitro and represses telomerase activity and telomerase reverse transcriptase mRNA expression in the cells. , 2004, Biological & pharmaceutical bulletin.

[120]  Paul Tempst,et al.  Different EZH2-containing complexes target methylation of histone H1 or nucleosomal histone H3. , 2004, Molecular cell.

[121]  Yi Zhang,et al.  The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. , 2004, Current opinion in genetics & development.

[122]  Kristian Helin,et al.  EZH2 is downstream of the pRB‐E2F pathway, essential for proliferation and amplified in cancer , 2003, The EMBO journal.

[123]  S. Dhanasekaran,et al.  The polycomb group protein EZH2 is involved in progression of prostate cancer , 2002, Nature.

[124]  Peter A. Jones,et al.  The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.

[125]  A. Schor,et al.  Tumour-stromal interactions: Phenotypic and genetic alterations in mammary stroma - implications for tumour progression , 2001, Breast Cancer Research.

[126]  P. Johnston,et al.  Capecitabine: a novel agent for the treatment of solid tumors , 2001, Anti-cancer drugs.

[127]  I. Fridovich,et al.  Radioprotective and tumor antiangiogenic effect of the novel synthetic superoxide dismutase (SOD) mimetic compounds , 2001, Breast Cancer Research.

[128]  Benny J Chen,et al.  Triptolide, A Novel Immunosuppressive and Anti-Inflammatory Agent Purified from a Chinese Herb Tripterygium Wilfordii Hook F , 2001, Leukemia & lymphoma.

[129]  Francisco Portillo,et al.  The transcription factor Snail controls epithelial–mesenchymal transitions by repressing E-cadherin expression , 2000, Nature Cell Biology.

[130]  P. Chiang,et al.  Activation of collagen IV gene expression in F9 teratocarcinoma cells by 3-deazaadenosine analogs. Indirect inhibitors of methylation. , 1992, The Journal of biological chemistry.

[131]  R. I. Glazer,et al.  3-Deazaneplanocin: a new and potent inhibitor of S-adenosylhomocysteine hydrolase and its effects on human promyelocytic leukemia cell line HL-60. , 1986, Biochemical and biophysical research communications.

[132]  R H Sarma,et al.  Delineation of the intimate details of the backbone conformation of pyridine nucleotide coenzymes in aqueous solution. , 1975, Biochemical and biophysical research communications.

[133]  M. Ardenne,et al.  [Demonstration of tumor inhibiting properties of a strongly immunostimulating low-molecular weight substance. Comparative studies with ifosfamide on the immuno-labile DS carcinosarcoma. Stimulation of the autoimmune activity for approx. 20 days by BA 1, a N-(2-cyanoethylene)-urea. Novel prophylactic , 1975, Arzneimittel-Forschung.

[134]  A. Sahebkar,et al.  Curcumin as a MicroRNA Regulator in Cancer: A Review. , 2016, Reviews of physiology, biochemistry and pharmacology.

[135]  X. Mo,et al.  Inhibitory Effect of Berberine on Zeste Homolog 2 (Ezh2) Enhancement in Human Esophageal Cell Lines , 2015 .

[136]  Tao Xi,et al.  Ursolic acid induces U937 cells differentiation by PI3K/Akt pathway activation. , 2014, Chinese journal of natural medicines.

[137]  Yangchao Chen,et al.  A potential antitumor ellagitannin, davidiin, inhibited hepatocellular tumor growth by targeting EZH2 , 2013, Tumor Biology.

[138]  S. Orkin,et al.  Targeted Disruption of the EZH 2 / EED Complex Inhibits EZH 2-dependent Cancer , 2013 .

[139]  Madhusudhan R. Papasani,et al.  YY 1 controls Ig j repertoire and B-cell development , and localizes with condensin on the Ig j locus , 2013 .

[140]  Bin Zhang,et al.  Triptolide inhibits histone methyltransferase EZH2 and modulates the expression of its target genes in prostate cancer cells. , 2013, Asian Pacific journal of cancer prevention : APJCP.

[141]  G. Ganji,et al.  EZH 2 inhibition as a therapeutic strategy for lymphoma with EZH 2-activating mutations , 2012 .

[142]  B. Bao,et al.  Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. , 2012, Cancer research.

[143]  Z. Ou,et al.  FOXC 1 , a target of polycomb , inhibits metastasis of breast cancer cells , 2011 .

[144]  K. Brew,et al.  The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. , 2010, Biochimica et biophysica acta.

[145]  R. Goldbohm,et al.  Brassica vegetables and cancer prevention. Epidemiology and mechanisms. , 1999, Advances in experimental medicine and biology.